Azitra (NYSEAMERICAN:AZTR) Posts Earnings Results, Beats Expectations By $0.31 EPS

Azitra (NYSEAMERICAN:AZTR) posted its earnings results on Tuesday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.31, Zacks reports.

Azitra Price Performance

Shares of Azitra stock traded down $0.04 during midday trading on Thursday, hitting $0.45. The company had a trading volume of 188,011 shares, compared to its average volume of 888,446. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.01. Azitra has a 12-month low of $0.43 and a 12-month high of $68.40.

About Azitra

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.